Business Wire

AI Expo: 7 Free Things You Can Get Involved with at the Leading AI Event in Amsterdam

Jaa

Arriving in Amsterdam on the 27-28 June, the second annual AI Expo Europe event will host 2 co-located events covering IoT and Blockchain, with 8,000 attendees expected to attend including CTO’s, CDO’s, Head’s of Innovation and Technology, IT Directors, Developers & Start-Up’s, OEM’s, Government, Automotive, Operators, Technology Providers, Investors, VCs and many more. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge and real-life experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006061/en/

A taster of the AI Expo Europe in Amsterdam (27-28th June). (Photo: Business Wire)

A taster of the AI Expo Europe in Amsterdam (27-28th June). (Photo: Business Wire)

1. The exhibition and start-up incubator zone

The event will host a dedicated start-up incubator zone where you can see the latest AI & IoT technologies and innovations in action, in addition to the vast exhibition of 300+ companies who will be showcasing their products and services within the field of AI, IoT & Blockchain. Expect to see demos and booths from Microsoft, IBM, PTC, Kore, Hercules, Thales, Rutronik, Enterprise Ethereum Alliance, BPU Holdings, Start-up Amsterdam, ML6, Bottos, Ortec Data Science, Adani, NTR Labs, Prosper BI and many more. Start-ups within the incubator zone include Aiir Innovations, Botsquad, Mercury.AI, IoTify, Porter, 3D Universium, Zazu, 904 Labs, Innovation in Motion, Blockhearts, Mind Trace, Sightcorp, Cupenya, Effect.Ai, Sodaq, Amberscript, BrainCreators, Clockworks to name a few. In addition, attendees can join speakers from Aiir Innovations, Mercury.AI and BrainCreators within the AI Technologies track on day 2 (28th June) as they explore innovative artificial intelligence techniques.

2. 10 Conference Tracks covering AI, IoT and Blockchain

Your Free Expo Pass will provide access to 10 conference tracks; AI Technologies , Data Analytics for AI & IoT, Developing for the IoT , Privacy & Security , IoT Innovations & Technologies , ICOs & Token Investments, Blockchain for Business, Developing Blockchain Applications , Blockchain Technologies and Blockchain Strategies. Register for your free expo pass here.

3. Keynote Panel: IoT and AI data analytics for intelligent decision making

Taking place on the 27th June at 10.15am within the Data Analytics for AI & IoT conference track, the Chief Data Scientist at Southern Water, a Data Scientist from Monsanto, a Data Scientist from Marel Poulty and the CEO from the predictive intelligence firm Prosper BI will be identifying target-rich, high-value data that can be used to generate business intelligence, looking at the use of cloud analytics platforms to derive value from AI & IoT data, and discussing the barriers to widespread AI/IoT/Big Data value delivery and how these might be overcome.

4. Machine Learning and AI: Do’s and Don’ts in the online food provider industry

Adrian Foltyn, Former Head/Director of Data Science at HelloFresh, the online food survival kit provider, will take to the stage within the Data & Analytics for AI & IoT track on the 27 June at 15.20pm. Adrian will discuss why preference data is at the core of the company’s operations as their predictive technologies forecast the food that their consumers want during certain seasons.

5. AI and Computer Vision – Intelligent Assistants and an extra pair of eyes…

Join Miriam Huijser, Co-Founder & Chief Research Officer at Aiir Innovations on 28 June within the AI Technologies conference track as she explores how intelligence assistants can be used to inspect aircraft engines using state-of-the-art computer vision techniques. Aiir Innovations is an Amsterdam based start-up that aims to bring artificial intelligence to the maintenance and aircraft industry. They will also be exhibiting within the start-up incubator zone within the expo floor.

6. 2 co-located events

Co-located with the IoT Tech Expo and the Blockchain Expo, the AI Exhibition and Conference will allow you to explore 3 ecosystems in 1 and discover how the convergence of these 3 areas is powering the future of technology!

7. Using Big Data to create intelligent data models

Within the dedicated Data Analytics for AI & IoT track on the 27 June at 14.40pm, join AI & IoT thought leaders as they take to the stage for a panel discussion. Hear from Christophe Eschenbrenner, IoT & Data Foundations Program Manager from Alstom Digital Mobility, Violeta Misheva, Data Scientist at ABN AMRO Bank N.V., Filippo F.G. Della Casa, Head of Analytics at Unipol and Dor Kedem, Senior Data Scientist at ING as they discuss the increased need for big data analytics to drive AI & Machine Learning across a range of industries.

Other event features include exclusive networking opportunities

Following the first day of the event, Speakers, Sponsors, Press, Ultimate, Gold and Expo Plus attendees are invited to attend an evening of networking.

The Beach House will host the official networking party. It is located at the entrance of The Beach and surrounded by stunning beach scenery. Set away from the busier main structures and with its own bar and terrace. Discuss the topics from the conferences and build relationships with like-minded companies and individuals.

To register for your networking (Ultimate/ Gold/ Expo Plus) pass, click here.

The final advance rate ends 15 June so if you are looking for full conference and networking access, you can save up to €150 on your conference and networking pass (Gold/Ultimate) when you book by then.

Or click here to register for your Free Expo Pass to the Europe 2018 event on the 27 - 28 June in Amsterdam.

You can find out more about the World Series 2018 and register for each event here:

AI Expo Europe27-28 th June 2018, RAI, Amsterdam

AI Expo North America28-29 th November 2018, Santa Clara, Silicon Valley

AI Expo Global25-26 th April 2019, Olympia Grand, London

Contact information

Anna Fry
Marketing Executive | AI Expo
anna@ai-expo.net
www.ai-expo.net/
+44 (0) 117 980 9020

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme